News

Applications are open for the MedTech Innovator Competition 2021 »

MedTech Innovator is the largest accelerator of medical devices in the world. We provide an unparalleled platform to support startups with the access, visibility, and network to bring their innovations to patients. Our alumni have raised over $2B in follow-on funding, brought 75 products to the market, and achieved 11 acquisitions. In its latest CipherBio report, Silicon Valley Bank recognized MTI as having the most active fundraising portfolio in 2020 of any accelerator.

Applications are open for the 2021 program. This is a highly selective and unique opportunity for startups and scale-ups to be showcased and gain access to healthcare stakeholders including investors, customers, and industry leaders such as Johnson & Johnson, Baxter, Olympus, W. L. Gore, Nipro, Edwards Lifesciences, Dexcom, Asahi Intecc, Fujikura, Jabil Healthcare, Maxim Integrated Products, and others. This year, up to $500,000 in non-dilutive prizes will be awarded.

Showcase at Leading Industry Conferences

Among other benefits, companies selected for the 2021 program will receive showcase presentation slots and one complimentary registration to the MedTech Innovator Summit and WSGR Medical Device Conference in June as well as The MedTech Conference powered by AdvaMed in September.

Prizes

Compete for up to $500,000 in non-dilutive cash prizes and in-kind awards

Who Should Apply?

All early to mid-stage medical device, diagnostic, or digital health companies are encouraged to apply. Preference for the Accelerator program will be given to companies that have not yet raised a Series B. All companies are eligible for the Showcase program.

Companies do not need to relocate to participate. MedTech Innovator does not charge or take equity for participation, and there is no application fee.

Apply Now

Recent News

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza